Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 30, 2025 07:05 ET | Source: Celcuity Inc.

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic...
June 20, 2025 06:30 ET | Source: Orion Oyj

CHMP recommends third indication for darolutamide for patients with advanced prostate cancer

ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for...
June 03, 2025 16:30 ET | Source: Orion Oyj

U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer

ORION CORPORATION PRESS RELEASE 3 JUNE 2025 at 23.30 EEST U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer Darolutamide is the first and only...
May 28, 2025 16:05 ET | Source: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

Broad and deep PSA responses achieved, with 59% PSA50 response rate (confirmed rate of 47%, and one additional response pending confirmation) and 24% PSA90 response rate (all confirmed) in patients...
May 27, 2025 08:00 ET | Source: ORIC Pharmaceuticals

ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...
May 21, 2025 07:05 ET | Source: Celcuity Inc.

Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences

MINNEAPOLIS, May 21, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian...
May 14, 2025 16:01 ET | Source: Celcuity Inc.

Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

The primary completion date of the PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is expected in June 2025 and a topline data readout is anticipated in the third quarter of 2025 Enrollment is...
May 07, 2025 07:05 ET | Source: Celcuity Inc.

Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
May 05, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Prostate Cancer Types Market Set for Robust Growth Through 2034, Driven by Advances in Targeted Therapies and Biomarker | DelveInsight

New York, USA, May 05, 2025 (GLOBE NEWSWIRE) -- Prostate Cancer Types Market Set for Robust Growth Through 2034, Driven by Advances in Targeted Therapies and Biomarker | DelveInsight The prostate...
April 28, 2025 16:30 ET | Source: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...